Unlike conditions like multiple sclerosis where there is a considerable amount of knowledge and several available approved treatment options that is not the case for neuromyelitis optica. As a result more work is needed to educate patients about what their treatment will be like.
Progressive multifocal leukoencephalopathy, also known as PML is a problem which can affect a select number of patients with multiple sclerosis as well as other conditions which involve the immune system. What can be done to address the condition is still being determined by the medical community.
“Multiple sclerosis usually begins with a relapsing-remitting (RRMS) phase characterized by clinical relapses and inflammatory demyelination evident on magnetic resonance imaging (MRI),” an Ohio based team began at ECTRIMS 2016.
Multiple sclerosis is perceived differently by the patient and physician – after all, they’re in two different boats. However, this disconnect could make managing the disease a more complicated journey.